Leland Gershell
Stock Analyst at Oppenheimer
(4.21)
# 1,526
Out of 4,690 analysts
750
Total ratings
40.5%
Success rate
7.6%
Average return
Main Sectors:
Stocks Rated by Leland Gershell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAPR Capricor Therapeutics | Upgraded: Buy | $54 | $8.29 | +551.39% | 28 | Aug 26, 2026 | |
| SPRB Spruce Biosciences | Reiterated: Buy | $230 | $63.40 | +262.78% | 6 | Aug 25, 2026 | |
| ARGX argenx SE | Reiterated: Buy | $1,037 → $1,100 | $1,019.49 | +7.90% | 19 | Aug 18, 2026 | |
| EQ Equillium | Rated: Buy | $7 | $2.18 | +221.10% | 4 | Aug 14, 2026 | |
| PALI Palisade Bio | Reiterated: Buy | $8 | $2.07 | +286.47% | 2 | Aug 11, 2026 | |
| BMRN BioMarin Pharmaceutical | Rated: Buy | $98 → $97 | $66.12 | +46.70% | 39 | Aug 7, 2026 | |
| LGND Ligand Pharmaceuticals | Reiterated: Buy | $326 | $281.72 | +15.72% | 4 | Aug 7, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $24 → $25 | $17.95 | +39.28% | 18 | Aug 7, 2026 | |
| IMVT Immunovant | Reiterated: Buy | $54 | $43.50 | +24.14% | 9 | Aug 7, 2026 | |
| CLYM Climb Bio | Maintained: Buy | $18 | $17.84 | +0.90% | 6 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $50 → $60 | $46.36 | +29.42% | 48 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $84.86 | - | 20 | Jul 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $30 | $3.85 | +679.22% | 2 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.86 | - | 2 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.87 | - | 8 | Jun 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $262 | $252.99 | +3.56% | 37 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $3.81 | +267.45% | 7 | Jun 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 → $28 | $3.97 | +605.29% | 21 | May 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $0.588 | +1,600.68% | 16 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $1.40 | +614.29% | 2 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $24.18 | - | 34 | Apr 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 | $5.13 | +289.86% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $35 → $21 | $7.25 | +189.66% | 2 | Feb 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $2.71 | +822.51% | 44 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $26.76 | - | 7 | Feb 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $2,000 | $30.93 | +6,366.21% | 4 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $8.74 | +105.95% | 11 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $113.35 | - | 6 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $2.87 | +39.37% | 3 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35 | $19.74 | +77.30% | 28 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $80 | $37.71 | +112.15% | 1 | Sep 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $490 | $240.08 | n/a | 42 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $1.47 | n/a | 20 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $38.10 | n/a | 10 | May 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $106 | $77.46 | n/a | 3 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $0.2215 | n/a | 19 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $4.16 | n/a | 17 | Dec 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $11 | $1.16 | n/a | 19 | Nov 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $2.20 | n/a | 16 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $4.44 | n/a | 6 | Oct 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $60 | $0.1288 | n/a | 11 | May 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $70 → $200 | $0.000001 | n/a | 11 | Mar 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $11.31 | n/a | 16 | Nov 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $8 | $0.0001 | n/a | 1 | Jun 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 | $0.40 | n/a | 11 | Jun 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $7 | $1.05 | n/a | 16 | May 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $2.30 | n/a | 7 | May 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $0.001 | n/a | 4 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $14.15 | n/a | 13 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $9.72 | n/a | 22 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.64 | n/a | 9 | Dec 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.0071 | n/a | 15 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.05 | n/a | 3 | May 10, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.23 | n/a | 9 | May 9, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $4.06 | n/a | 9 | Apr 3, 2019 |
Capricor Therapeutics
Aug 26, 2026
Upgraded: Buy
Price Target: $54
Current: $8.29
Upside: +551.39%
Spruce Biosciences
Aug 25, 2026
Reiterated: Buy
Price Target: $230
Current: $63.40
Upside: +262.78%
argenx SE
Aug 18, 2026
Reiterated: Buy
Price Target: $1,037 → $1,100
Current: $1,019.49
Upside: +7.90%
Equillium
Aug 14, 2026
Rated: Buy
Price Target: $7
Current: $2.18
Upside: +221.10%
Palisade Bio
Aug 11, 2026
Reiterated: Buy
Price Target: $8
Current: $2.07
Upside: +286.47%
BioMarin Pharmaceutical
Aug 7, 2026
Rated: Buy
Price Target: $98 → $97
Current: $66.12
Upside: +46.70%
Ligand Pharmaceuticals
Aug 7, 2026
Reiterated: Buy
Price Target: $326
Current: $281.72
Upside: +15.72%
Trevi Therapeutics
Aug 7, 2026
Reiterated: Buy
Price Target: $24 → $25
Current: $17.95
Upside: +39.28%
Immunovant
Aug 7, 2026
Reiterated: Buy
Price Target: $54
Current: $43.50
Upside: +24.14%
Climb Bio
Aug 7, 2026
Maintained: Buy
Price Target: $18
Current: $17.84
Upside: +0.90%
Aug 6, 2026
Reiterated: Buy
Price Target: $50 → $60
Current: $46.36
Upside: +29.42%
Jul 7, 2026
Downgraded: Hold
Price Target: n/a
Current: $84.86
Upside: -
Jun 24, 2026
Maintained: Buy
Price Target: $30
Current: $3.85
Upside: +679.22%
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $3.86
Upside: -
Jun 22, 2026
Rated: Hold
Price Target: n/a
Current: $1.87
Upside: -
Jun 15, 2026
Reiterated: Buy
Price Target: $262
Current: $252.99
Upside: +3.56%
Jun 15, 2026
Reiterated: Buy
Price Target: $14
Current: $3.81
Upside: +267.45%
May 20, 2026
Reiterated: Buy
Price Target: $25 → $28
Current: $3.97
Upside: +605.29%
May 15, 2026
Reiterated: Buy
Price Target: $10
Current: $0.588
Upside: +1,600.68%
May 6, 2026
Reiterated: Buy
Price Target: $10
Current: $1.40
Upside: +614.29%
Apr 13, 2026
Rated: Hold
Price Target: n/a
Current: $24.18
Upside: -
Mar 31, 2026
Reiterated: Buy
Price Target: $20
Current: $5.13
Upside: +289.86%
Feb 27, 2026
Maintained: Buy
Price Target: $35 → $21
Current: $7.25
Upside: +189.66%
Feb 12, 2026
Reiterated: Buy
Price Target: $25
Current: $2.71
Upside: +822.51%
Feb 10, 2026
Rated: Hold
Price Target: n/a
Current: $26.76
Upside: -
Nov 14, 2025
Maintained: Buy
Price Target: $2,000
Current: $30.93
Upside: +6,366.21%
Nov 7, 2025
Maintained: Buy
Price Target: $18
Current: $8.74
Upside: +105.95%
Nov 4, 2025
Downgraded: Hold
Price Target: n/a
Current: $113.35
Upside: -
Oct 14, 2025
Reiterated: Buy
Price Target: $4
Current: $2.87
Upside: +39.37%
Sep 29, 2025
Reiterated: Buy
Price Target: $35
Current: $19.74
Upside: +77.30%
Sep 3, 2025
Initiated Coverage: Buy
Price Target: $80
Current: $37.71
Upside: +112.15%
Aug 4, 2025
Upgraded: Buy
Price Target: $490
Current: $240.08
Upside: n/a
Sep 16, 2024
Maintained: Buy
Price Target: $25
Current: $1.47
Upside: n/a
May 20, 2024
Rated: Hold
Price Target: n/a
Current: $38.10
Upside: n/a
May 14, 2024
Maintained: Buy
Price Target: $106
Current: $77.46
Upside: n/a
Mar 28, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $0.2215
Upside: n/a
Dec 18, 2023
Maintained: Buy
Price Target: n/a
Current: $4.16
Upside: n/a
Nov 13, 2023
Maintained: Buy
Price Target: $11
Current: $1.16
Upside: n/a
Jul 10, 2023
Maintained: Buy
Price Target: n/a
Current: $2.20
Upside: n/a
Oct 4, 2022
Downgraded: Hold
Price Target: n/a
Current: $4.44
Upside: n/a
May 26, 2022
Maintained: Buy
Price Target: $60
Current: $0.1288
Upside: n/a
Mar 21, 2022
Maintained: Buy
Price Target: $70 → $200
Current: $0.000001
Upside: n/a
Nov 16, 2021
Reiterated: Hold
Price Target: n/a
Current: $11.31
Upside: n/a
Jun 4, 2021
Initiated Coverage: Buy
Price Target: $8
Current: $0.0001
Upside: n/a
Jun 2, 2021
Rated: Buy
Price Target: $12
Current: $0.40
Upside: n/a
May 18, 2021
Rated: Buy
Price Target: $7
Current: $1.05
Upside: n/a
May 7, 2021
Initiated Coverage: Buy
Price Target: $42
Current: $2.30
Upside: n/a
May 6, 2021
Maintained: Hold
Price Target: n/a
Current: $0.001
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $14.15
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $9.72
Upside: n/a
Dec 31, 2020
Rated: Hold
Price Target: n/a
Current: $0.64
Upside: n/a
Sep 11, 2020
Rated: Hold
Price Target: n/a
Current: $0.0071
Upside: n/a
May 10, 2019
Reiterated: Buy
Price Target: $7
Current: $1.05
Upside: n/a
May 9, 2019
Rated: Hold
Price Target: n/a
Current: $1.23
Upside: n/a
Apr 3, 2019
Reiterated: Buy
Price Target: $8
Current: $4.06
Upside: n/a